MagForce, a medical technology company focused on nanomedicine in oncology, has announced that it has treated a recurrent glioblastoma patient using NanoTherm therapy.
The therapy involves the direct injection of magnetic nanoparticles into the tumour, and their subsequent heating by an alternating magnetic field.
The therapy was carried out at the University of Giessen and Charité University Medical Center Berlin.
Based on an individual patient agreement, the treatment costs are being covered by a German state insurance company.
MagForce CEO Peter Heinrich said that, through its collaborations with experts in both and internationally, the company plans to further develop this treatment approach for a variety of solid tumour indications with high medical need.
